Brent Scott's Colleagues at Oxford Pharmaceuticals, LLC
Brent Scott's Contact Details
(205) 434-9649
Oxford Pharmaceuticals, LLC
Brent Scott's Company Details
Oxford Pharmaceuticals is a manufacturer of generic oral solid tablets located in Birmingham, AL. Our new $30 million, state-of-the-art 150,000 sq. ft was FDA approved in 2019. Our engineering, quality control and process development, along with extensively experienced regulatory scientists ensures our control of product quality, safety, and efficacy standards. Our purpose is to provide quality products at competitive prices of our oral solid dose ANDAs through our cost-effective manufacturing capabilities. Manufacturing capabilities provide for the most current and efficient processes at large scale, and our automated Packaging Line Serialization meets 2023 requirements. The mezzanine warehouse has 25,000 sq. ft of storage space, and our main warehouses includes shipping & receiving and finished product cages and vaults approved for Scheduled Drug CII - CV. Brands & Products: Oxford Pharmaceuticals is launching a basket of over 30+ generic pharmaceutical products. Our diversified product portfolio along with our in-house cost competitive service delivery distribution channel is our core strength of commitment to deliver maximum profitability to our respective customers, all with consistent and continuous supply. Our Story: Start-Up Pharmaceutical Company Oxford broke ground for the construction of our generic drug manufacturing and distribution facility in Birmingham, AL in September 2015. The facility opened in August of 2016. Built to comply with Good Manufacturing Practices (GMP), Oxford was inspected and FDA approved in May 2019 with the first product approval in July 2019. We launched our first products just at the start of the Pandemic and have never shut down with continued growth each month with new launches ongoing. Oxford's employment capacity is approx. 200 people. The Oxford Plant is constructed on a 27-acre site in Birmingham, AL that is privately held with roots to our UK investor and CEO, an Oxford, England Scholar.